Tocilizumab Prevents Progression of Early Systemic Sclerosis–Associated Interstitial Lung Disease is a research paper published in Arthritis & Rheumatology (2021). On theSindex it has a DataRank of 5.5. It has been cited 194 times, with 100 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.791
From this paper's citation signal
Citation Network Contribution
4.7
From 100 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Grant: 1R01‐AR070470‐01A1
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Grant: K24‐AR‐063129
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Grant: T32‐AR007080
NIAMS NIH HHS
Grant: R43 AR063129
NIAMS NIH HHS
Grant: T32 AR007080
NIAMS NIH HHS
Grant: R01 AR070470
NIAMS NIH HHS
Grant: K24 AR063120
National Institutes of Health
Grant: 3T32AR007080-45S1
Scientist Training in Rheumatology Research
National Institutes of Health
Grant: 1R01AR070470-01A1
Systemic Sclerosis-Associated Interstitial Lung Disease Response Index
National Institutes of Health
Grant: 1R43AR063129-01
Syk blockade in bullous skin diseases
FWCI
21.33
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals